Medical Devices

ADVANCING TECHNOLOGY, IMPROVING LIVES
Treatment with Abbott’s *Absorb* stent helped firefighter Michal Gurgul, of Czerniec, Poland, recover from a heart attack and get back to saving others’ lives.

**BREAKTHROUGH DEVICES**
Volunteer firefighter Michal Gurgul was responding to an emergency when he collapsed with chest pains. His brother Konrad (*pictured at far left*) rushed him to the hospital, where doctors discovered that he had three blocked arteries. They restored blood flow using our *Absorb* naturally dissolving stent.

*Absorb* is just one of the breakthrough technologies in Abbott’s device portfolio. By focusing on innovation that addresses growing and sustainable market needs, Abbott can help deliver improved patient outcomes while lowering overall healthcare costs.

**A GLOBAL LEADER**
With the acquisition of St. Jude Medical, Abbott further strengthened our presence in this segment, creating a global leader in medical devices. We offer more options, more breakthrough inventions and extensive expertise across the areas of diabetes, cardiovascular, and neuromodulation. Demand for these technologies is increasing as the prevalence of conditions associated with aging — such as heart disease and diabetes — rises, positioning Abbott well for future growth.

**ABSORB STENT**
Abbott’s naturally dissolving stent system opens blocked arteries before being absorbed, leaving behind a restored vessel in a natural state, free of a permanent metal implant.
2016 BUSINESS HIGHLIGHTS

Our Absorb bioresorbable stent and FreeStyle Libre flash glucose-monitoring system were named to Popular Science magazine’s “Best of What’s New” list of important innovations in 2016

CARDIOVASCULAR
• Absorb bioresorbable stent approved in the United States and Canada

STRUCTURAL HEART
• MitraClip NT, Abbott’s latest-generation transcatheter mitral-valve repair device, launched in the United States and Europe

DIABETES CARE
• FreeStyle Libre system was CE marked for pediatric use in Europe and approved for adult use in Australia, Brazil, China, and Japan. FreeStyle Libre is now available in 32 countries.
• FreeStyle Libre Pro system, Abbott’s sensing technology for use by physicians, was approved in the United States
• Launched Libre Link and Libre Link-up mobile smartphone apps in Europe
Changing the Testing Paradigm for People with Diabetes

Abbott’s FreeStyle Libre system was designed with patients in mind. By providing an alternative to routine finger sticks, it offers a true breakthrough in routine glucose testing.1 This system uses a small sensor worn on the back of the upper arm to automatically measure and continuously store glucose readings, day and night, for up to 14 days.

A quick scan of the sensor provides a current glucose reading, as well as the previous 8 hours of glucose data, including an indicator telling the user whether their glucose level has been rising or falling.

1. Global prevalence of diabetes among adults rose from 4.7% in 1980 to 8.5% in 2014.2